Navigation Links
FDA Approves New surgery Treatment for Farsightedness

The US Food and Drug Administration has approved a new treatment for farsightedness known as conductive keratoplasty. The technique uses radiofrequency energy to// shrink small areas of the cornea, the transparent coat on the surface of the eyeball. Unlike laser in situ keratomileusis (LASIK), in which the surface of the eye is reshaped using a laser, conductive keratoplasty does not require cutting or tissue removal.

The treatment may become the preferred method of correcting farsightedness in older patients. Conductive keratoplasty is very comfortable and convenient, especially for older patients who don't want something as invasive or as complex as LASIK. It is also helpful for older patients who might have dry eye or surface epithelial irregularities, which could be exacerbated by LASIK.

The average age of patients who undergo LASIK is in the early 40s, while for conductive keratoplasty, the average age for patients has been 58. LASIK is approved for higher degrees of farsightedness and astigmatism, which is blurry vision usually caused by an uneven curvature of the cornea. Conductive keratoplasty could also be safer for patients with glaucoma, because keratoplasty does not require the temporary elevation of pressure within the eye that is induced during LASIK.

The procedure is normally conducted with topical anesthesia. Afterwards, patients normally experience some eye irritation, which resolves within 24 to 48 hours. Most of the patients have been followed for 2 years, and they have expressed overwhelming satisfaction with the procedure.
'"/>




Page: 1

Related medicine news :

1. FDA Approves Contraceptive Ring
2. FDA Approves New HIV Drug, Viread
3. FDA Approves Birth Control Skin Patch
4. FDA Approves New Arthritis Drug, Bextra
5. FDA Approves Elidel Cream for Eczema
6. FDA Approves New Anti-Clotting Drug
7. FDA Approves Anti-Cancer Cell Drug - Zevalin
8. FDA Approves Remodulin for Pulmonary Hypertension
9. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/18/2017)... La. (PRWEB) , ... February 18, 2017 , ... ... released today provides the latest information and contact points to easily connect elderly ... home care, assisted living, and elder-care funding. It also conveys material on this ...
(Date:2/17/2017)... Murfreesboro, TN (PRWEB) , ... February 17, 2017 ... ... EHR mobility has not kept pace. Enovate Medical has introduced an innovative workstation ... 20 years of supporting nurses, the Encore Mobile EHR Workstation offers a lightweight, ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... Falls Church, VA (PRWEB) , ... ... ... to Integrate FDA Device Approval and Reimbursement , **An FDAnews Webinar**, Feb. ... , What are the critical reimbursement questions manufacturers should be asking ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 ... manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The methods ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... TOWN, South Africa , Feb. 20, 2017 /PRNewswire/ ... of illness and non-communicable diseases (NCDs) across sub-Saharan Africa, ... prescription drugs. The growing incidence of more Western lifestyle ... respiratory disease, in addition to infectious and parasitic illness, ... with a business opportunity of $40.8 billion ...
(Date:2/20/2017)... SAN FRANCISCO , February 20, 2017 /PRNewswire/ ... (CSF) management market  is anticipated to reach USD ... report by Grand View Research, Inc. Constant evaluation ... hydrocephalus management is expected to drive growth in ... the investment for development of novel and improved ...
(Date:2/20/2017)... 20, 2017 Acute, Chronic and Prophylaxis GVHD ... at a CAGR of 7% from 2016-2021 and CAGR of 3% from ... from 2016 to 2027. The market is estimated at $0.36bn in 2016, ... ... discover how you can exploit the future business opportunities emerging in this ...
Breaking Medicine Technology: